Results 101 to 110 of about 601,377 (310)

Mixed chimerism: Preclinical studies and clinical applications [PDF]

, 1999
Traditional approaches to allogeneic stem cell transplantation have relied on the use of toxic high-dose conditioning therapy to achieve allogeneic engraftment and control of underlying disease.
Storb, Rainer, McSweeney, Peter A
core   +1 more source

A novel quinazolinone insulin receptor inhibitor and its synergy with an EGFR inhibitor in glucose‐driven glioblastoma

Molecular Oncology, EarlyView.
The novel styrylquinazolinone‐based molecule W1B effectively suppresses glioblastoma by inhibiting IGF1R and EGFR. In high‐glucose microenvironments driving tumor resistance, W1B acts synergistically with the EGFR inhibitor dacomitinib. This combination safely blocks compensatory survival signaling in zebrafish xenograft models. Showcasing promising in
Patryk Rurka, Wioleta Cieślik, Wojciech Płaziński, Katarzyna Stępnik, Anna Boguszewska‐Czubara, Elżbieta Kot, Robert Musioł, Mateusz Jasica, Anna Mrozek‐Wilczkiewicz, Katarzyna Malarz   +9 more
wiley   +1 more source

Treatment options for Achilles tendinopathy:a scoping review of preclinical studies [PDF]

BACKGROUND: Achilles tendinopathy (AT) management can be difficult, given the paucity of effective treatment options and the degenerative nature of the condition. Innovative therapies for Achilles tendinopathy are therefore direly needed. New therapeutic
Millar, Neal L, Neal L. Millar, Maas, Huub; id_orcid, Smit, Theodoor Henri, Maarten H. Moen, Agyeman-Prempeh, Nathanael Opoku, Theodoor Henri Smit, George L. Burchell, Huub Maas, Moen, Maarten H, Burchell, George L, Nathanael Opoku Agyeman-Prempeh   +11 more
core   +1 more source

Epigenetic heterogeneity and plasticity in therapy‐induced tumor states through single‐cell multi‐omics

Molecular Oncology, EarlyView.
Single‐cell multi‐omics reveals epigenetic heterogeneity across therapy‐adaptive tumor states, including quiescent/dormant, drug‐tolerant persister, and EMT‐like phenotypes. By linking regulatory features with state‐associated biomarkers, these approaches inform biomarker‐guided therapeutic strategies for evolving tumors.
Hee Jung Kim, Hwiyeong Lee, Jin Hong, Daechan Park   +3 more
wiley   +1 more source

A Review of Preclinical Studies to Understand Fear During Adolescence [PDF]

, 2015
A Review of Preclinical Studies to Understand Fear During ...
Jee Hyun Kim (13075509), DE Ganella (14876710)   +1 more
core  

Translatability of preclinical to early clinical tolerable and pharmacologically active dose ranges for central nervous system active drugs [PDF]

, 2023
The primary purpose of this study was to assess the translatability of preclinical to early clinical tolerable and pharmacologically active dose ranges for central nervous system (CNS) active drugs.
Ferreira, Guilherme S, van Meer, Peter J K, Boon, Wouter P C, van Gerven, Joop M A, Schellekens, Huub, Moors, Ellen H M, Dijkstra, Francis M, Stuurman, Frederik E, Veening-Griffioen, Désirée H   +8 more
core  

PAK1 activation drives divergent resistance mechanisms to aromatase inhibition and tamoxifen in a luminal: A breast cancer model

Molecular Oncology, EarlyView.
Breast cancer remains a major cause of cancer death in women, frequently developing endocrine therapy resistance. This study demonstrates that upregulated p21‐activated kinase 1 (PAK1) activity drives resistance to tamoxifen and long‐term estrogen deprivation in ER+ breast cancer models.
Luisa Schwarzmüller, Janina Müller, Efstathios‐Iason Vlachavas, Lukas Beumers, Lena Fleischhacker, Sara Burmester, Angelika Wörner, Sabine Karolus, Dominic Helm, Cindy Körner, Stefan Wiemann   +10 more
wiley   +1 more source

Analysis of Current Rules and Regulations for Preclinical Studies of Radiopharmaceuticals [PDF]

SCIENTIFIC RELEVANCE. Owing to specific aspects of their development and use, radiopharmaceuticals require separate rules and regulations for preclinical studies. However, current legislation and regulations on the organisation and conduct of preclinical
K. E. Ternovskaya, A. D. Sklyarenko, A. E. Surnina, A. S. Lunev, K. A. Petrosova, А. I. Nigmatulina   +5 more
core   +2 more sources

Inhibition of cyclin‐dependent kinases 12/13 using CT7439 as a treatment for colorectal cancer with CDK12 upregulation

Molecular Oncology, EarlyView.
The proposed mechanism of action for the CDK12/13 inhibitor and cyclin K degrader, CT7439. CDK12/13 inhibition interrupts transcription elongation, leading to increased DNA damage that results in cell death. This agent is a potentially novel treatment option for patients with colorectal cancer. Created in BioRender. Cyclin‐dependent kinase (CDK) 12 and
Wylie K. Watlington, Divya L. Dayanidhi, Mohammad Zokaasadi, John B. Mantyh, Pelumi D. Olawuni, Gabrielle Rupprecht, Jeremy M. Force, Shannon McCall, Ashwani K. Bahl, David S. Hsu, Jason A. Somarelli   +10 more
wiley   +1 more source

Optimized design and analysis of preclinical intervention studies in vivo [PDF]

, 2016
Recent reports have called into question the reproducibility, validity and translatability of the preclinical animal studies due to limitations in their experimental design and statistical analysis.
Poutanen, Matti, Laajala, T. D., Kaur, A., Aittokallio, T., Laajala, Teemu D., Aittokallio, Tero, Poutanen, Matti,, Fey, V., Knuuttila, M., Kaur, Amanpreet, Aho, Eija, Oksala, R., Knuuttila, Matias, Fey, Vidal, Jumppanen, M., Oksala, Riikka, Westermarck, Jukka, Aho, E., Huhtaniemi, R., Westermarck, J., Makela, S., Jumppanen, Mikael, Huhtaniemi, Riikka, Makela, Sari   +23 more
core   +1 more source